A study led by scientists at the Center for Cancer Research (CCR) at the American National Cancer Institute (NCI) has revealed a way to promote the continued growth of tumors in theRead More…
3D Bio-printing Model Changes Anti-cancer Drug Development and Anti-tumor Therapy
Researchers at the University of Minnesota have developed a way to study cancer cells, which could lead to new and more effective treatments. They have developed a new method to study theseRead More…
Nine characteristics shared by the most successful mAb
The path to finding a therapeutic antibody that leads to significant medical improvements is often complicated, long, and costly. Many criteria have to be taken into account in order to begin theRead More…
Sixteen New Tumor Drugs First Approved in 2018
In 2018, from the approval of JNJ’s apalutamide in the United States on February 14 to that of larotrectinib on November 26, a total of 16 new tumor drugs were approved forRead More…
Nat Genet：Scientists Discover New Target for Immunotherapy Following 2018 Nobel Prize for Medicine
Following the 2018 Nobel Prize for Medicine, global attention is now more than ever turned toward the promise of immunotherapy in oncology. According to a recent study published in the international journalRead More…
The First Rituxan Biosimilar Is Expected to Be Approved by FDA
B cell lymphoma is a solid tumor that occurs in B cells, including Hodgkin’s lymphoma and non-Hodgkin’s lymphoma. In numerous types of B cell lymphoma, classic Hodgkin’s lymphoma and nodular lymphocyte areRead More…
First Approval for Fremanezumab-vfrm
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AJOVYTM (fremanezumab-vfrm) injection for the preventive treatment of migraine in adults. AJOVY, aRead More…
Antibody Combo Knocks Down HIV in Clinical Trials
A mix of two monoclonal antibodies against HIV tamped down virus levels in patients not taking antiretroviral medication, according to the results of two early-stage clinical trials reported in nature. After several infusionsRead More…
The First Single Domain Antibody (sdAb) Drug Was Approved by EMA
On September 3, 2018, the EMA approved the single domain antibody (sdAb) drug Cablivi (Caplacizumab) in Sanofi for the treatment of adult-acquired Thrombotic Thrombocytopenic Purpura (aTTP). Cablivi became the first specific aTTPRead More…
Nature Communication: New Targets for Lung Cancer Are Expected to Bring Innovative Treatments
Lung cancer is one of the cancers with the lowest survival rates. What’s even more frustrating is that in the past four decades, although the overall survival rate of cancer patients hasRead More…